by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing
Crohn’s disease: DUET-CD study (combination of guselkumab and golimumab) Similar to ulcerative colitis, this study tests the combination of the two drugs for Crohn’s disease and compares it with the single application. The aim is to determine which therapy...
by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing
Ulcerative colitis: DUET-UC study (combination of guselkumab and golimumab) This study examines the efficacy and safety of combining the two medications guselkumab and golimumab compared to using each medication individually. The study is aimed at patients with...
by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing
Ulcerative colitis: COMMAND Study (Risankizumab) This study focuses on the drug risankizumab. It examines various phases, including a 52-week maintenance phase and open-label extensions, to assess safety and efficacy in patients who have previously responded to...
by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing
Ulcerative colitis: ABTECT Maintenance Study This study tests the long-term safety and efficacy of the drug ABX464, taken once daily as maintenance therapy. It is aimed at patients who have not responded to other treatments—both conventional and advanced...
by Pauline Lauterbach | Jan 16, 2026 | Completed, For participants
ABTECT-1 Study on Ulcerative Colitis A recent study tested ABX464, a new drug for people with moderate to severe ulcerative colitis who have not responded to standard treatments. Participants received either ABX464 or a placebo to determine if the drug can alleviate...
by Pauline Lauterbach | Jan 16, 2026 | Active, seeking participants, For participants
Ulcerative colitis: MIRACLE study Worum geht es in dieser Studie? Die MIRACLE-Studie vergleicht zwei Behandlungsansätze für Patient:innen, die in den letzten 12 Monaten neu mit mittelschwerer bis schwerer Colitis ulcerosa diagnostiziert wurden: Frühzeitige Behandlung...
